For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230705:nRSE9578Ea&default-theme=true
RNS Number : 9578E Eco Animal Health Group PLC 05 July 2023
5 July 2023
ECO Animal Health Group plc
(''ECO", the "Company" or the "ECO Group")
(AIM: EAH)
Notice of Results & Investor Presentation
ECO Animal Health Group plc, a leader in the development, registration and
marketing of pharmaceutical products for global animal health markets, will
issue its results for the year ended 31 March 2023 on Monday 10 July 2023.
Investor Presentation
David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live
presentation covering the company's FY Results for the period ended 31 March
2023. The online presentation will take place on Wednesday 12 July at 2.30pm
UK time.
This event is open to all existing and potential shareholders and registration
is free. Questions can be submitted during the presentation and will be
addressed at the end of it. Please register using the following link:
https://www.equitydevelopment.co.uk/news-and-events/ecoanimalhealth-fyresultspresentation-12july2023
(https://www.equitydevelopment.co.uk/news-and-events/ecoanimalhealth-fyresultspresentation-12july2023)
For further information please contact:
ECO Animal Health Group plc 020 8447 8899
David Hallas (CEO)
Christopher Wilks (CFO)
IFC Advisory 020 3934 6630
Graham Herring
Zach Cohen
Singer Capital Markets (Nominated Adviser & Joint Broker) 020 7496 3000
Phil Davies
George Tzimas
Investec (Joint Broker) 020 7597 5970
Gary Clarence
Lydia Zychowska
Carlo Spingardi
Equity Development 020 7065 2692
Hannah Crowe
Matt Evans
About ECO Animal Health
ECO Animal Health Group plc researches, develops and commercialises products
for livestock. Our business strategy is to generate shareholder value by
achieving the maximum sales potential from the existing product portfolio
whilst investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORUSRVROUUBRAR